PARP inhibitors are a class of targeted cancer therapies that block the activity of Poly (ADP-ribose) polymerase (PARP), a key enzyme involved in DNA repair. By exploiting defects in the homologous recombination repair (HRR) pathway, especially in tumors with BRCA1 or BRCA2 mutations, PARP inhibitors selectively kill cancer cells while sparing normal tissues.
In this article, we’ll explore the mechanism of action of PARP inhibitors, their approved drugs and clinical applications, key biomarkers of response, resistance mechanisms, and the future perspectives of PARP-targeted therapies in cancer treatment.
The Role of PARP in DNA Damage Response
The maintenance of genomic stability is essential for cell survival. Among the key players in this process are the Poly (ADP-ribose) polymerases (PARPs), particularly PARP1 and PARP2, which detect and repair single-strand DNA breaks (SSBs) through the base excision repair (BER) pathway.
When DNA damage occurs, PARP1 rapidly binds to the broken DNA site and catalyzes the transfer of ADP-ribose units from NAD⁺ to itself and other repair proteins — a process called PARylation. This modification recruits essential DNA repair factors such as XRCC1, DNA ligase III, and DNA polymerase β, facilitating the repair of single-strand breaks and restoring DNA integrity.
Beyond BER, PARPs also participate in other DNA repair mechanisms, including double-strand break repair and the regulation of chromatin structure during the DNA damage response. By coordinating these pathways, PARP enzymes act as molecular sensors that determine cell fate after genotoxic stress.
Because cancer cells often rely heavily on PARP-mediated repair due to existing defects in other repair pathways, blocking PARP activity can push them toward apoptosis — a concept that forms the scientific basis for PARP inhibitor therapy.
Mechanism of Action of PARP Inhibitors
PARP inhibitors act by targeting the enzymatic activity of PARP1 and PARP2, enzymes responsible for repairing single-strand DNA breaks (SSBs) through the base excision repair (BER) pathway. When these enzymes are inhibited, unrepaired SSBs accumulate and eventually lead to the formation of double-strand breaks (DSBs) during DNA replication — lesions that are far more lethal to the cell.
In healthy cells, DSBs are repaired through the homologous recombination repair (HRR) pathway, mediated by BRCA1 and BRCA2 proteins. However, in tumor cells with BRCA mutations or homologous recombination deficiency (HRD), this repair system is defective. Consequently, when PARP activity is blocked, these cells cannot repair the accumulating DNA damage, leading to genomic instability and ultimately cell death — a process known as synthetic lethality.
In addition to catalytic inhibition, PARP inhibitors can cause PARP trapping, where the PARP–DNA complex becomes physically stuck on DNA, obstructing replication forks and further enhancing cytotoxicity. The strength of PARP trapping varies among drugs — Talazoparib shows potent trapping activity, while Olaparib and Rucaparib exhibit moderate effects.
Approved PARP Inhibitor Drugs and Their Clinical Applications
Several PARP inhibitors have been approved for clinical use, marking a major milestone in targeted cancer therapy. These drugs are primarily used to treat tumors with BRCA1/BRCA2 mutations or homologous recombination deficiency (HRD), conditions that make cancer cells highly sensitive to DNA repair inhibition.
1. Olaparib (Lynparza)
Developed by AstraZeneca, Olaparib was the first PARP inhibitor approved by the FDA. It is indicated for ovarian, breast, pancreatic, and prostate cancers with BRCA mutations. Olaparib can be used as monotherapy or maintenance therapy following chemotherapy, significantly improving progression-free survival in HRD-positive patients.
2. Rucaparib (Rubraca)
Rucaparib, produced by Clovis Oncology, is approved for the treatment of recurrent ovarian and prostate cancers associated with BRCA mutations. It also serves as a maintenance treatment after platinum-based chemotherapy.
3. Niraparib (Zejula)
Developed by GSK, Niraparib has shown efficacy in both BRCA-mutated and BRCA wild-type ovarian cancers, expanding the scope of PARP inhibitor therapy. Its oral administration and broad activity profile make it suitable for long-term maintenance therapy.
4. Talazoparib (Talzenna)
Talazoparib, by Pfizer, is notable for its strong PARP trapping ability, making it highly potent even at low concentrations. It is approved for HER2-negative metastatic breast cancer with germline BRCA mutations.
5. Veliparib (under investigation)
Although not yet widely approved, Veliparib is being investigated in combination with chemotherapy and immunotherapy for multiple cancer types, including lung and triple-negative breast cancers.
Biomarkers for PARP Inhibitor Sensitivity
The effectiveness of PARP inhibitors largely depends on the tumor’s underlying DNA repair status. Identifying reliable biomarkers of sensitivity is therefore crucial for selecting patients who are most likely to benefit from PARP-targeted therapy.
1. BRCA1 and BRCA2 Mutations
Mutations in the BRCA1 and BRCA2 genes remain the strongest predictors of PARP inhibitor response. These genes encode essential proteins for homologous recombination repair (HRR) — a high-fidelity mechanism that fixes double-strand DNA breaks. Tumors with defective BRCA-mediated repair are unable to correct the DNA damage induced by PARP inhibition, leading to synthetic lethality and tumor cell death.
2. Homologous Recombination Deficiency (HRD)
Beyond BRCA mutations, many tumors exhibit homologous recombination deficiency (HRD) due to alterations in other HR-related genes such as RAD51, PALB2, ATM, or CHEK2. HRD status can be detected through genomic instability assays, which assess the extent of chromosomal rearrangements characteristic of HR-deficient cancers.
3. Genomic Instability Signatures
HRD-positive tumors often show specific genomic patterns — including loss of heterozygosity (LOH), telomeric allelic imbalance, and large-scale state transitions — which can serve as measurable biomarkers for patient selection in clinical practice.
4. Functional Biomarkers
Recent studies suggest that functional assays assessing RAD51 foci formation or DNA repair efficiency in tumor cells may provide dynamic indicators of PARP inhibitor sensitivity, complementing genetic testing.
Mechanisms of Resistance to PARP Inhibitors
Despite their clinical success, many patients eventually develop resistance to PARP inhibitors, reducing their long-term efficacy.
1. Restoration of Homologous Recombination Repair (HRR)
One of the most common resistance mechanisms involves secondary mutations in BRCA1 or BRCA2 that restore their normal protein function. This reactivation of homologous recombination repair (HRR) enables tumor cells to repair double-strand breaks, thereby escaping synthetic lethality.
2. Loss of PARP1 Function
Paradoxically, some resistant cancer cells acquire loss-of-function mutations in PARP1, the main target of PARP inhibitors. Without PARP1, the drugs cannot effectively trap the enzyme on DNA, leading to reduced cytotoxicity.
3. Upregulation of Drug Efflux Pumps
Overexpression of ATP-binding cassette (ABC) transporters, such as ABCB1 (P-glycoprotein), increases drug efflux from the cell, decreasing intracellular PARP inhibitor concentrations and diminishing their effectiveness.
4. Stabilization of Replication Forks
In HR-deficient tumors, replication forks are normally unstable, contributing to genomic collapse. However, some resistant cells can stabilize replication forks by protecting them from nucleolytic degradation, allowing DNA replication to continue even in the absence of HRR.
5. Activation of Alternative DNA Repair Pathways
Cancer cells may also compensate by activating non-homologous end joining (NHEJ) or alternative end-joining (alt-EJ) pathways, providing alternative means to repair DNA double-strand breaks and survive PARP inhibition.
6. Tumor Microenvironment and Epigenetic Changes
Epigenetic reprogramming and changes in the tumor microenvironment, such as hypoxia, can alter DNA repair gene expression and contribute to adaptive resistance mechanisms.
Overall, resistance to PARP inhibitors reflects the remarkable adaptability of cancer cells. Ongoing research aims to overcome these mechanisms through combination therapies, new PARP inhibitor designs, and biomarker-driven treatment optimization.
Combination Therapies Involving PARP Inhibitors
While PARP inhibitors have demonstrated remarkable efficacy in BRCA-mutated and HRD-positive cancers, combining them with other therapeutic agents can further enhance their antitumor activity and overcome drug resistance. Several combination strategies are currently being explored in preclinical and clinical studies.
1. PARP Inhibitors and Chemotherapy
Combining PARP inhibitors with DNA-damaging chemotherapeutic agents, such as platinum-based drugs (cisplatin, carboplatin) or topoisomerase inhibitors, can amplify DNA damage beyond the cancer cell’s repair capacity. However, this approach requires careful dosing due to overlapping hematologic toxicities like anemia and thrombocytopenia.
2. PARP Inhibitors and Radiotherapy
Radiation therapy induces extensive DNA breaks, and blocking PARP-mediated repair increases radiosensitivity. This radiosensitization effect makes PARP inhibitors promising agents for combination with radiotherapy in tumors resistant to conventional radiation doses.
3. PARP Inhibitors and Immunotherapy
Recent research has revealed strong synergy between PARP inhibition and immune checkpoint blockade (anti–PD-1/PD-L1 therapy). PARP inhibitors can increase tumor mutational burden, promote neoantigen release, and activate the STING pathway, thereby enhancing the immune response. Clinical trials are currently investigating combinations such as Olaparib plus Durvalumab or Niraparib plus Pembrolizumab.
4. PARP Inhibitors and Targeted Therapies
Co-targeting DNA repair and signaling pathways can improve treatment precision. For instance, combining PARP inhibitors with ATR, CHK1, or PI3K inhibitors can disrupt multiple DNA repair and survival mechanisms simultaneously, showing promise in resistant tumors.
5. PARP Inhibitors and Anti-Angiogenic Agents
Drugs like Bevacizumab, an anti-VEGF monoclonal antibody, have been successfully combined with Olaparib in ovarian cancer. Hypoxia induced by anti-angiogenic therapy enhances HRD, sensitizing tumor cells to PARP inhibition.
Combination therapies thus represent a key direction for improving the clinical benefits of PARP inhibitors. The ultimate goal is to design personalized regimens that exploit multiple vulnerabilities in cancer cells while minimizing toxicity.
Side Effects and Safety Profile of PARP Inhibitors
While PARP inhibitors offer targeted efficacy against BRCA-mutated and HRD-positive cancers, they are not without side effects. Understanding their safety profile is essential for clinicians to manage toxicities and maintain treatment adherence.
1. Hematologic Toxicities
The most common adverse effects are related to the blood system:
- Anemia – fatigue, pallor, and reduced oxygen-carrying capacity
- Thrombocytopenia – increased risk of bleeding
- Neutropenia – higher susceptibility to infections
Hematologic toxicities are generally dose-dependent and reversible with dose adjustments or treatment interruption.
2. Gastrointestinal Effects
Patients frequently report nausea, vomiting, diarrhea, and loss of appetite. These side effects are often mild to moderate and manageable with antiemetic medications or dietary modifications.
3. Fatigue and General Malaise
Fatigue is one of the most commonly reported symptoms, impacting quality of life. Supportive care and treatment scheduling adjustments can help mitigate this effect.
4. Rare but Serious Toxicities
- Myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Rare but serious, usually after long-term use or in combination with chemotherapy.
- Pneumonitis and liver enzyme elevation: Less common, requiring monitoring and potential discontinuation.
5. Safety Management
Regular blood counts, liver function tests, and clinical monitoring are recommended during therapy. Early recognition and intervention are key to maintaining treatment efficacy while minimizing risks.
Overall, the benefit-risk profile of PARP inhibitors remains favorable, especially in patients with genetic vulnerabilities that render tumors highly sensitive to DNA repair inhibition.
Conclusion
PARP inhibitors have revolutionized targeted cancer therapy, offering a highly effective treatment for BRCA-mutated and HRD-positive tumors. By blocking DNA repair and exploiting synthetic lethality, these drugs selectively kill cancer cells while sparing healthy tissues.
Despite challenges such as resistance and toxicity, ongoing research, combination therapies, and precision oncology approaches continue to expand their clinical potential. As our understanding of DNA repair mechanisms and biomarkers improves, PARP inhibitors are poised to play an increasingly central role in personalized cancer treatment.
Frequently Asked Questions about PARP Inhibitors
1. What cancers are treated with PARP inhibitors?
PARP inhibitors are primarily used to treat ovarian, breast, prostate, and pancreatic cancers, especially in patients with BRCA1/BRCA2 mutations or homologous recombination deficiency (HRD).
2. How do PARP inhibitors target BRCA mutations?
PARP inhibitors exploit synthetic lethality. In BRCA-mutated tumors, the homologous recombination repair (HRR) pathway is defective. Blocking PARP-mediated DNA repair leads to accumulation of DNA damage and selective death of cancer cells.
3. Are PARP inhibitors effective in non-BRCA cancers?
Yes, PARP inhibitors can be effective in tumors with other HRD-related mutations or genomic instability. Their use is expanding through biomarker-driven patient selection and combination therapies.
4. What are the most common side effects of PARP inhibitors?
The most frequent side effects include fatigue, nausea, anemia, thrombocytopenia, and neutropenia. Most are manageable with dose adjustments or supportive care. Rare but serious effects include myelodysplastic syndrome (MDS) or acute leukemia (AML).
5. Can PARP inhibitors be combined with immunotherapy?
Yes. Combining PARP inhibitors with immune checkpoint inhibitors (e.g., anti–PD-1/PD-L1) can enhance tumor immunogenicity and immune response, showing promising results in clinical trials for ovarian and breast cancers.
References:
Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017 Mar 17;355(6330):1152-1158. doi: 10.1126/science.aam7344.
Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020 Mar 1;34(5-6):360-394. doi: 10.1101/gad.334516.119.
Zeng Y, Arisa O, Peer CJ, Fojo A, Figg WD. PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics. Semin Oncol. 2024 Feb-Apr;51(1-2):19-24. doi: 10.1053/j.seminoncol.2023.09.005.
Cortesi L, Rugo HS, Jackisch C. An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Target Oncol. 2021 May;16(3):255-282. doi: 10.1007/s11523-021-00796-4.
